SB235375 is a potent and selective antagonist of the human neurokinin-3 (hNK-3) receptor, designed through optimization of the 2-phenyl-4-quinolinecarboxamide scaffold. It exhibits high affinity for the hNK-3 receptor with significantly greater binding selectivity over hNK-2 and hNK-1 receptors. In vitro, SB235375 blocks NK-3 receptor-mediated contractions and calcium mobilization. In vivo, it demonstrates oral and intravenous activity in animal models against NK-3 receptor-driven responses.